Last reviewed · How we verify
AK127 in combination with AK112
At a glance
| Generic name | AK127 in combination with AK112 |
|---|---|
| Sponsor | Akeso |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Phase Ib/II Clinical Study of AK127 in Combination With AK112 in Patients With Advanced Solid Tumors (PHASE1, PHASE2)
- A Study of AK112 in Patients With Advanced Hepatocellular Carcinoma (HCC) (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- AK127 in combination with AK112 CI brief — competitive landscape report
- AK127 in combination with AK112 updates RSS · CI watch RSS
- Akeso portfolio CI